ID Genomics Founder: We must personalize how we treat bacteria
ID Genomics Founder Evgeni Sokurenko said the company intends to have FDA approval for the test by 2018. It will cost about $10.
Zavante raises $45M to bring antibiotic fosfomycin to U.S.
So why is Zavante brushing the dust off fosfomycin? After all, it was actually first tested in the 1960s in Spain, but had been ruled as fairly ineffective in comparison to other antibiotics on the market.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Iterum launches with $40M for novel antibiotic
Iterum Therapeutics, based in Ireland but financed in the U.S., is comprised largely of the team that launched Durata Therapeutics - which was acquired two years ago by Actavis for $675 million.
scPharmaceuticals’ drug/device combo aims at replacing IVs in antibiotic drug delivery
scPharmaceuticals has raised $3.6 million in what looks to be a bridge financing round for its drug/device combo that could replace IV use in treating heart failure and infections.
Startup’s drug could prevent antibiotic-related hearing loss
Certain powerful antibiotics come with a catch - they can cause serious hearing loss. Oricula Therapeutics is developing a drug that could be used to prevent the hearing loss - and allow wider use of these antibiotics.
The Potentiator: Spero Therapeutics gets $30M to up potency of existing antibiotics
Spero Therapeutics is also developing next-generation DHFR antibiotics.
presented by
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Zavante gets $10M for CRE-treating antibiotic to enter clinic
Zavante Therapeutics' antibiotic is scheduled to enter clinical trials next quarter, with aims to treat complicated urinary tract infections.
CONVERGE: Antibiotic investment trends and what can Scandinavia teach us about HAI?
Six or seven years ago, it was tough to raise funds for antibiotics. But we are seeing that pendulum shift dramatically and seeing more companies invest.
The FDA is enforcing a new rule to reduce the use of antibiotics in animals we eat
The threat of superbugs is a real concern. For that reason, the FDA is providing new regulations concerning the use of antibiotics in animals we eat.
Google Ventures: These eight life sciences techs are the most promising – and worthy of investment
Google Ventures President and CEO Bill Maris highlights the eight life sciences technologies he thinks are the most game-changing - including CRISPR, artificial intelligence and understanding the microbiome.
Maximize Revenue and Patient Care with Strategic Weight Loss Management
We will highlight Build My Health's revenue practice management tools, which could help physician practices add up to $250,000 to their practices.
Nabriva Therapeutics raises $120M for drugs that attack antibiotic resistant bacteria that cause pneumonia
Transatlantic antibiotics maker Nabriva Therapeutics just raised an enormous swath of cash – it just closed a $120 million Series B round to treat serious and highly resistant bacterial infections. It’s validation for a largely underused class of antibiotics – pleuromutilins – and a step in the direction to address global antibiotic resistance. The first, $50 million tranche […]
Are Superbugs on the Rise?
Many proclaim that the discovery of penicillin was perhaps the most important medical discovery of all times. With the use of penicillin, patients survived previous deadly infections and life expectancy rose. Many of the complications that arose from infections, such as rheumatic heart disease, became nearly eradicated. Following that, many more new and more powerful […]
Thanks to resistance, drug companies retiring antibiotic after antibiotic
Antibiotic resistance is taking its toll on the pharmaceutical industry: Drugs are getting retired from clinical circulation, because many have basically been rendered ineffective, according to an article from Washington University of St. Louis. It highlights the work of WUSTL’s Michael Kinch, associated vice chancellor of its Center for Research Innovation in Business: The number […]
Innovators will swing balance in national initiative to manage antibiotic-resistant bacteria threat
A year after the airing of a scary documentary by Frontline called attention to nightmare bacteria that knows no effective antibiotic remedy, the Obama administration set down the beginnings of a strategy to ramp up regional monitoring programs and an effective way to report detection. The Centers for Disease Control, which is playing a central […]
UW spinout is hoping a drug could stave off hearing loss caused by antibiotics
University of Washington spinout Oricula Therapeutics said today it’s secured funding and intellectual property that will allow it to move forward with developing a way to prevent hearing loss associated with a class of antibiotics called aminoglycosides. Aminoglycosides are low-cost antibiotics that have historically been highly effective in treating infections caused by gram-negative bacteria, such […]